SPG(SH:600529) Sou Hu Cai Jing·2026-01-17 18:28Core Viewpoint - Shandong Pharmaceutical Glass Co., Ltd. plans to issue up to 199,084,233 A-shares at a price of 16.25 yuan per share, aiming to raise no more than 3.235 billion yuan to supplement working capital, with the issuance subject to various approvals [1][4][5]. Company Announcements - The company held its 11th Board of Directors' fifth meeting, approving the proposal for a private placement of shares to China International Pharmaceutical Health Co., Ltd. and Shandong Yaoxin Health Industry Co., Ltd. [1][4]. - The issuance will result in China International becoming the controlling shareholder, with the actual controller changing to China National Pharmaceutical Group, ultimately controlled by the State Council's State-owned Assets Supervision and Administration Commission [2][6]. Financial Details - The total market capitalization of Shandong Pharmaceutical Glass is currently 13.996 billion yuan, ranking 22nd in the medical device sector and 1495th in the A-share market [1]. - The company reported that the net proceeds from the previous fundraising amounted to 1.842 billion yuan, which was fully utilized for specific projects, with a remaining balance of approximately 769.76 million yuan for future project construction [3]. Shareholder Changes - The original controlling shareholder, Luzhong Investment, will see its shareholding decrease from 19.50% to 15.00% following the issuance [4][6]. - After the issuance, the combined shareholding of China International and Shandong Yaoxin will be 23.08%, leading to a change in control [2][7]. Compliance and Governance - The company has confirmed that there are no commitments to guarantee returns to the issuance targets, nor any financial assistance provided to them [2]. - The independent directors have stated that the issuance plan complies with legal regulations and does not harm the interests of minority shareholders [5][7].